JP2011510008A5 - - Google Patents

Download PDF

Info

Publication number
JP2011510008A5
JP2011510008A5 JP2010543198A JP2010543198A JP2011510008A5 JP 2011510008 A5 JP2011510008 A5 JP 2011510008A5 JP 2010543198 A JP2010543198 A JP 2010543198A JP 2010543198 A JP2010543198 A JP 2010543198A JP 2011510008 A5 JP2011510008 A5 JP 2011510008A5
Authority
JP
Japan
Prior art keywords
independently
pain
construction
disease
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010543198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011510008A (ja
JP5583028B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/030887 external-priority patent/WO2009091760A1/en
Publication of JP2011510008A publication Critical patent/JP2011510008A/ja
Publication of JP2011510008A5 publication Critical patent/JP2011510008A5/ja
Application granted granted Critical
Publication of JP5583028B2 publication Critical patent/JP5583028B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010543198A 2008-01-18 2009-01-14 オキサゾリジン及びチアゾリジン選択的サブタイプアルファ2アドレナリン作用薬並びにこれらの使用方法 Expired - Fee Related JP5583028B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2215208P 2008-01-18 2008-01-18
US61/022,152 2008-01-18
PCT/US2009/030887 WO2009091760A1 (en) 2008-01-18 2009-01-14 Oxazolidine and thiazolidine selective subtype alpha 2 adrenergic agents and methods for use thereof

Publications (3)

Publication Number Publication Date
JP2011510008A JP2011510008A (ja) 2011-03-31
JP2011510008A5 true JP2011510008A5 (enExample) 2012-03-01
JP5583028B2 JP5583028B2 (ja) 2014-09-03

Family

ID=40345009

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010543198A Expired - Fee Related JP5583028B2 (ja) 2008-01-18 2009-01-14 オキサゾリジン及びチアゾリジン選択的サブタイプアルファ2アドレナリン作用薬並びにこれらの使用方法

Country Status (7)

Country Link
US (2) US8735399B2 (enExample)
EP (1) EP2242753B1 (enExample)
JP (1) JP5583028B2 (enExample)
AU (1) AU2009205473B8 (enExample)
BR (1) BRPI0906875A2 (enExample)
CA (1) CA2712190A1 (enExample)
WO (1) WO2009091760A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809379B2 (en) * 2008-01-18 2014-08-19 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
US20120190719A1 (en) * 2009-08-26 2012-07-26 Allergan, Inc. Methods of treating motor disorders with alpha-2b andrenergic receptor agonists
PL2605771T3 (pl) 2010-08-16 2018-10-31 Allergan, Inc. Sposób aktywacji limfocytów t regulacyjnych za pomocą agonistów receptorów alfa-2b-adrenergicznych

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2392827T3 (es) 2003-12-23 2012-12-14 Basf Se Compuestos de 1-(azolin-2-il)amino-1,2-difeniletano para combatir insectos, arácnidos y nematodos
AP2008004547A0 (en) * 2005-12-22 2008-08-31 Basf Se Petsticidal compositions
US7709507B2 (en) * 2006-05-17 2010-05-04 Allergan, Inc. Therapeutic fluoroethyl ureas
WO2008123821A1 (en) 2007-03-01 2008-10-16 Albireo Ab 4, 5-dihydro-lh-imidazol-2-amine derivatives for use in the treatment of respiratory, cardiovascular, neurological or gastrointestinal disorders
ES2442298T3 (es) * 2008-01-18 2014-02-11 Allergan, Inc. Agentes alfa 2 adrenérgicos selectivos de subtipo y métodos para usarlos
US8809379B2 (en) * 2008-01-18 2014-08-19 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof

Similar Documents

Publication Publication Date Title
JP2011522774A5 (enExample)
JP2011509297A5 (enExample)
JP2007516941A5 (enExample)
JP2004517852A5 (enExample)
JP2015531764A5 (enExample)
JP2008526888A5 (enExample)
JP2005527579A5 (enExample)
CN1178935C (zh) 用作α-2-肾上腺素受体拮抗剂的1,3-二取代吡咯烷
AR079542A1 (es) Derivados de benzamida sustituidos, proceso para su preparacion y su uso en el tratamiento de enfermedades mediadas por taars.
JP2006516977A5 (enExample)
JP2014502982A5 (enExample)
JP2011517443A5 (enExample)
JP2009538867A5 (enExample)
JP2011510008A5 (enExample)
JP2015503610A5 (enExample)
JP2005521671A5 (enExample)
TNSN07365A1 (fr) Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence a corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 de l'histamine non-imidazole-alkylamines
BR112013024312A2 (pt) derivados de amina heterocíclica
JP2019525939A5 (enExample)
CN1074766C (zh) 烷氨基苯并噻唑及-苯并噁唑衍生物
JP2011518858A5 (enExample)
JP2012526832A5 (enExample)
JP2013523846A5 (enExample)
JP2012508275A5 (enExample)
JP2017509676A5 (enExample)